Tumor biomarkers and efficacy in patients treated with trastuzumab emtansine + pertuzumab versus standard of care in HER2-positive early breast cancer: an open-label, phase III study (KRISTINE)

By sjmartinez • January 12, 2023

de Haas SL, Slamon DJ, Martin M, Press MF, Lewis GD, Lambertini C, Prat A, Lopez-Valverde V, Boulet T, Hurvitz SA. Tumor biomarkers and efficacy in patients treated with trastuzumab emtansine + pertuzumab versus standard of care in HER2-positive early breast cancer: an open-label, phase III study (KRISTINE). Breast Cancer Res. 2023 Jan 11;25(1):2. doi: 10.1186/s13058-022-01587-z. PMID: 36631725.

Tags: Hematology/Oncology, HER2-positive breast cancer, KRISTINE, pertuzumab, Publications, Trastuzumab emtansine, Tumor biomarkers

SGNDV-001: disitamab vedotin with pembrolizumab in HER2-expressing locally advanced or metastatic urothelial carcinoma

Powles TB, Grande E, Alimohamed N, Oliveira N, Sridhar SS, Drakaki A, Kanesvaran R, Loriot Y, Necchi A, Franco S, Jiang D, Apolinario K, Zhang[...]

Revolutionizing breast cancer treatment: the promise of antibody-drug conjugates

Alkassis S, Glaspy JA, Bardia A. Revolutionizing breast cancer treatment: the promise of antibody-drug conjugates. Clin Adv Hematol Oncol. 2025 Jul-Aug;23(5):290-299. PMID: 40728347.

A Patient’s Journey With Modern Melanoma Therapy

Black AC, Senofsky G. A Patient's Journey With Modern Melanoma Therapy. Cureus. 2025 Jun 26;17(6):e86811. doi: 10.7759/cureus.86811. PMID: 40718227; PMCID: PMC12296936.